Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

• Egile Nagusiak: Xiaoting Liu (Egilea), Xiao-xue Liu (Egilea), Wenqing Shao (Egilea), Yi Zhou (Egilea), Jing Zhang (Egilea), Cuirong Zhao (Egilea), Chengwu Shen (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

ObjectiveBoth camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical Products Administration of China (NMPA) for the first-line treatment of local advanced or metastatic sqNSCLC. However, the co...